I
IFM Therapeutics
A biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system
About IFM Therapeutics
IFM Therapeutics is a biopharmaceutical startup that specializes in the development of first-in-class medicines aimed at controlling or enhancing immune responses for the treatment of inflammation-driven diseases and cancer. The company operates in the pharmaceutical market, serving a broad range of clients, including patients suffering from these conditions and other healthcare stakeholders.
The company's business model revolves around the discovery and development of novel drugs. It has a strong track record, with three novel programs progressing from inception to the clinic within the first 3.5 years. The company has also successfully closed two major deals, demonstrating its financial viability and growth potential.
IFM Therapeutics has made significant strides in its research and development efforts. It has identified novel and proprietary NLRP3 and STING agonists, which are molecules that bind to a protein and activate it, potentially leading to a therapeutic effect in the body. The company has also demonstrated preclinical proof of concept for both these agonists.
The company has secured substantial funding, closing a $27M Series A round and a $31M Series A financing for its subsidiary, IFM Tre. It has also successfully sold two of its entities, IFM Uno and IFM Tre, for $2.32B and $1.575B respectively, further bolstering its financial position.
Currently, IFM Therapeutics is conducting various clinical trials, including Phase 2 trials investigating the use of its NLRP3 antagonist, IFM-2427, in treating familial cold auto-inflammatory syndrome and symptomatic knee osteoarthritis, among other conditions.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Boston, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 71.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Dec 2019 | $56M | $222M | Omega Funds · Atlas Venture | — |
| SERIES AOther financing | Jul 2018 | $31M | $124M | Atlas Venture · Bristol-Myers Squibb | — |
Growth signals
Latest recorded traffic for IFM Therapeutics is 2.9K monthly website visits, up 70.6% over the last three months. IFM Therapeutics's team declined 57.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
IFM Therapeutics in the Boston ecosystem
The IFM Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Atlas Venture
Novartis
Bristol-Myers SquibbOmega Funds
Other known investors1 additional known investor
EPFL Swiss Federal Polytechnic School of Lausanne
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IFM Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IFM Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









